e primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials / / JAMA. 2006. Vol. 295. P. 306-313.
12. Wilson R., Gazzala J., House J. Aspirin in primary and secondary prevention in elderly adults revisited / / South. Med. J. 2012. Vol. 105. P. 82-86.
13. Pignone M., Alberts M.J., Colwell J.A. et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation / / Circulation. 2010. Vol. 121. P. 2694-2701.
14. De Berardis G., Sacco M., Strippoli GF et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials / / BMJ. 2009. Vol. 339. B4531.
15. Zhang C., Sun A., Zhang P. et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis / / Diabetes Res. Clin. Pract. 2010. Vol. 87. P. 211-218.
16. Belch J., MacCuish A., Campbell I. et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease / / BMJ. 2008. Vol. 337. A1840.
17. Ogawa H., Nakayama M., Morimoto T. et al. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial / / JAMA. 2008. Vol. 300. P. 2134-2141.
18. De Berardis G., Sacco M., Evangelista V. et al. ACCEPT-D Study Group. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins / / Trials. 2007. Vol. 8. P. 21.
19. British Heart Foundation. ASCEND: A Study of Cardiovascular Events in Diabetes. ctsu.ox.ac.uk/ascend. Accessed April 1, 2013.
20. Rocca B., Santilli F., Pitocco D. et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to lowdose aspirin in patients with and without diabetes / / J. Thromb. Haemost. 2012. Vol. 10. P. 1220-1230.
21. Hernandez-Diaz S., Garcia Rodriguez LA Cardioprotective aspirin users and their excess risk for upper gastrointestinal complications / / BMC Med. 2006. Vol. 4. P. 22.
22. Rockall TA, Logan RF, Devlin HB, Northfield TC Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage / / BMJ. 1995. Vol. 311. P. 222-226.
23. Nelson M.R., Reid C.M., Ames D.A. et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE...
